FIELD: medicine; pharmaceuticals.
SUBSTANCE: group of inventions relates to the chemical-pharmaceutical industry and is a method for the preparation of a stable pharmaceutical complex formulation and the formulation itself comprising angiotensin II receptor blocker candesartan; HMG-CoA reductase inhibitor rosuvastatin; a pharmaceutically acceptable alkalizing agent, calcium carbonate and a lubricant that is polyethylene glycol.
EFFECT: group of inventions allows preparing a complex formulation with improved stability and content uniformity of both active agents.
5 cl, 2 dwg, 10 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMBINED COMPOSITION | 2016 |
|
RU2736942C2 |
| PHARMACEUTICAL COMBINED DRUG | 2014 |
|
RU2639818C2 |
| PHARMACEUTICAL COMBINATION PREPARATION CONTAINING THE INHIBITOR OF HMG-CoA REDUCTASE AND INHIBITOR OF CHOLESTEROL ABSORPTION | 2014 |
|
RU2649811C2 |
| THERAPEUTIC TREATMENT | 2004 |
|
RU2358737C2 |
| CONTROLLED RELEASE COMPLEX PHARMACEUTICAL COMPOSITION CONTAINING ANGIOTENSIN-II RECEPTOR BLOCKERS AND HYDROXIMETHYLGLUTARYL-COA REDUCTASE INHIBITORS | 2007 |
|
RU2453307C2 |
| PHARMACEUTICAL COMPOSITION, CONTAINING CALCIUM SALT OF ROSUVASTATIN | 2012 |
|
RU2602911C2 |
| PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING CARDIOVASCULAR DISEASES | 2011 |
|
RU2491070C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING HMG-CoA REDUCTASE INHIBITOR AND ACE INHIBITOR | 2016 |
|
RU2750934C2 |
| APPLICATION OF SUBSTITUTED CYANOPYROLIDINES AND COMBINED PREPARATIONS CONTAINING THEM FOR TREATMENT OF LIPIDEMIA AND ASSOCIATED DISEASES | 2003 |
|
RU2362555C2 |
| COMBINED COMPOSITION CONTAINING METFORMIN OF SUSTAINED RELEASE AND INHIBITOR HMG-CoA-REDUCTASE OF IMMEDIATE RELEASE | 2014 |
|
RU2651460C2 |
